In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests |
| |
| Authors: | A L Barry R N Jones C Thornsberry L W Ayers T L Gavan E H Gerlach |
| |
| Institution: | (1) Clinical Microbiology Institute, PO Box 947, 97062 Tualatin, Oregon, USA;(2) Kaiser-Permanente Regional Laboratory, 97015 Clackamas, Oregon, USA;(3) Centers for Disease Control, 30333 Atlanta, Georgia, USA;(4) Ohio State University Medical Center, 43210 Columbus, Ohio, USA;(5) Cleveland Clinic Foundation, 44106 Cleveland, Ohio, USA;(6) St. Francis Hospital and Medical Center, 67214 Wichita, Kansas, USA |
| |
| Abstract: | The activity of two new quinolones, A-56619 and A-56620, was compared in vitro to that of norfloxacin and ciprofloxacin against 6,699 bacterial isolates in four separate clinical laboratories. The overall percentage of strains susceptible to designated concentrations were as follows: 99.1% for norfloxacin (MIC 4.0
g/ml), 96.1% for ciprofloxacin (MIC1.0
g/ml), 96.8% for A-56620 (MIC 2.0
g/ml) and 96.1% for A-56619 (MIC 4.0
g/ml). For disk diffusion susceptibility tests 10
g A-56619 disks are tentatively recommended with interpretive standards of  18mm for susceptibility and 13mm for resistance; 5
g A-56620 disks may be used with tentative standards of 19mm for susceptibility and 14mm for resistance. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
